NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia

• On 7 Apr 2026 NervGen announced a successful End‑of‑Phase‑2 meeting with the U.S. FDA and received alignment on the design of its Phase 3 “RESTORE” registrational study of NVG‑291 in chronic tetraplegia.
• RESTORE will be a randomized, double‑blind, placebo‑controlled trial enrolling ~150 subjects at up to 60 sites in the U.S. and Canada, with primary endpoint change in GRASSP Quantitative Prehension at Week 12.
• The company confirmed that Phase 3 initiation remains on track for mid‑2026; earlier Phase 1b/2a CONNECT SCI data support the chosen endpoints, dosing regimen, and demonstrate clinically meaningful functional improvements.
• No safety concerns were reported; prior studies showed no treatment‑related serious adverse events.

• Regulatory Milestone: FDA alignment on Phase 3 design is a concrete step toward a potential NDA filing. It removes a major source of uncertainty that typically depresses biotech valuations.
• Timing: The study is slated to start mid‑2026, meaning data read‑outs could arrive in 2028‑2029, providing a clear future catalyst.
• Comparison to prior expectations: Earlier releases (Nov 2025 – Q3 results, Mar 2026 full‑year results) already indicated an upcoming End‑of‑Phase‑2 meeting and a Phase 3 start “by early 2026.” The April 2026 announcement confirms those expectations and adds concrete trial design details. Because the market already anticipated a regulatory checkpoint, the news is material but not a surprise – it upgrades certainty rather than creates a new narrative.
• Risk mitigation: No adverse safety signals were disclosed; the FDA’s agreement on endpoints reduces the risk of later trial redesign.

Overall, the announcement materially improves the company’s risk‑adjusted outlook and should be priced positively by the market, though the impact is tempered by the fact that the Phase 3 start was already expected.

• Core business: Development of NVG‑291, a neuroreparative peptide aimed at restoring motor function in spinal cord injury (SCI).
• Flagship program: Phase 1b/2a CONNECT SCI study (chronic tetraplegia) demonstrated statistically significant improvements in hand function (GRASSP scores), bladder control, and spasticity with an excellent safety profile.
• Regulatory status: Fast‑Track designation (FDA) and Orphan Drug designation (EMA). FDA Type C meeting (Sept 2024) confirmed multiple accelerated pathways; End‑of‑Phase‑2 alignment achieved Apr 2026.